Endothelin-1 limits vascular smooth muscle beta-adrenergic receptor sensitivity by a PKC-dependent pathway.
Endothelin-1 reduces the chronotropic and inotropic effects of the beta-adrenoceptor agonist isoproterenol in rabbit isolated atria. Vascular interactions between endothelin-1 and isoproterenol have not been reported. Rings of the rabbit aorta without endothelium were mounted on myographs to measure isometric tension. Vessels were precontracted to similar levels with phenylephrine (30 micromol/L) or endothelin-1 (30 nmol/L). Relaxation to isoproterenol and forskolin were obtained. Vascular sensitivity (pD2) to isoproterenol was not different in the presence of endothelin-1 (7.6 +/- 0.3; n = 13) and phenylephrine (7.5 +/- 0.3; n = 11). The maximal relaxation (Emax) however, was doubled (P < 0.05) by endothelin-1 (42 +/- 5%), as compared with phenylephrine (23 +/- 4%). In the presence of endothelin-1, chelerythrine (protein kinase C inhibitor; 10 micromol/L) increased (P < 0.05) vascular sensitivity to isoproterenol (8.6 +/- 0.4, n = 7), but had no influence on the Emax. In contrast, in the presence of phenylephrine, pD2 was unaffected by chelerythrine, whereas the Emax to isoproterenol was increased (P < 0.05; 50 +/- 4%, n = 8). Vascular sensitivity and Emax to forskolin were similar in the presence of endothelin-1 and phenylephrine. In conclusion, endothelin-1 reduces vascular sensitivity to isoproterenol in a PKC-dependent pathway. The permissive effect of endothelin-1 appears to directly target the beta-adrenoceptor/G protein complex upstream of adenylate cyclase.
D000470:Alkaloids; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects; D053119:Benzophenanthridines; D005576:Colforsin / Q000008:administration & dosage / Q000493:pharmacokinetics; D016572:Cyclosporine / Q000008:administration & dosage / Q000493:pharmacokinetics; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics*; D005260:Female; D007545:Isoproterenol / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D008297:Male; D009126:Muscle Relaxation / Q000187:drug effects / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D010617:Phenanthridines / Q000008:administration & dosage / Q000493:pharmacokinetics; D010656:Phenylephrine / Q000008:administration & dosage / Q000493:pharmacokinetics; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology*; D011817:Rabbits; D011943:Receptors, Adrenergic, beta / Q000187:drug effects* / Q000502:physiology*; D017466:Receptors, Endothelin / Q000502:physiology; D014664:Vasodilation / Q000187:drug effects
D000470:Alkaloids; D053119:Benzophenanthridines; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D010617:Phenanthridines; D011943:Receptors, Adrenergic, beta; D017466:Receptors, Endothelin; D005576:Colforsin; D010656:Phenylephrine; D016572:Cyclosporine; C016299:chelerythrine; D011493:Protein Kinase C; D007545:Isoproterenol